Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Immunitybio Inc IBRX

Healthcare Biotechnology
Immunitybio, Inc. is a vertically integrated, clinical-stage biotechnology company developing therapies and vaccines that bolster the natural immune system to defeat cancers and infectious diseases. Using its proprietary platforms that amplify both the innate and adaptive branches of the immune system, its advances therapies and vaccines to defeat urologic and other cancers, as well as... see more

Recent & Breaking News (NDAQ:IBRX)

IBRX SHAREHOLDER ALERT: Jakubowitz Law Reminds ImmunityBio Shareholders of a Lead Plaintiff Deadline of August 29, 2023

PR Newswire July 14, 2023

ROSEN, A LEADING LAW FIRM, Encourages ImmunityBio, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - IBRX

PR Newswire July 13, 2023

SHAREHOLDER ACTION NOTICE: The Schall Law Firm Encourages Investors in ImmunityBio, Inc. with Losses of $100,000 to Contact the Firm

Newsfile July 13, 2023

DEADLINE ACTION NOTICE: The Schall Law Firm Encourages Investors in ImmunityBio, Inc. with Losses of $500,000 to Contact the Firm

Accesswire July 13, 2023

IBRX LAWSUIT ALERT: Levi & Korsinsky Notifies ImmunityBio, Inc. Investors of a Class Action Lawsuit and Upcoming Deadline

PR Newswire July 13, 2023

ROSEN, GLOBAL INVESTOR COUNSEL, Encourages ImmunityBio, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - IBRX

Newsfile July 12, 2023

SHAREHOLDER ACTION REMINDER: The Schall Law Firm Encourages Investors in ImmunityBio, Inc. with Losses of $100,000 to Contact the Firm

Newsfile July 12, 2023

INVESTOR ACTION ALERT: Scott+Scott Attorneys at Law LLP Reminds Investors That a Securities Class Action Has Been Filed Against ImmunityBio, Inc. (NASDAQ: IBRX); Lead Plaintiff Deadline is August 29, 2023

Business Wire July 12, 2023

SHAREHOLDER ACTION ALERT: The Schall Law Firm Encourages Investors in ImmunityBio, Inc. with Losses of $100,000 to Contact the Firm

Accesswire July 12, 2023

HAGENS BERMAN, NATIONAL TRIAL ATTORNEYS, Encourages ImmunityBio (IBRX) Investors with Substantial Losses to Contact Firm's Attorneys, Securities Fraud Class Action Pending

Newsfile July 11, 2023

SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in ImmunityBio, Inc. of Class Action Lawsuit and Upcoming Deadline - IBRX

PR Newswire July 11, 2023

ImmunityBio, Inc. (IBRX) Stock News: Investors with Large Losses Should Contact Robbins LLP Regarding ImmunityBio, Inc. Class Action

Business Wire July 11, 2023

ROSEN, Top Ranked Investor Counsel, Encourages ImmunityBio, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - IBRX

Newsfile July 11, 2023

Deadline Reminder: Law Offices of Howard G. Smith Reminds Investors of Looming Deadline in the Class Action Lawsuit Against ImmunityBio, Inc. (IBRX)

Business Wire July 11, 2023

SHAREHOLDER ACTION ALERT: The Schall Law Firm Encourages Investors in ImmunityBio, Inc. with Losses of $100,000 to Contact the Firm

Newsfile July 11, 2023

INVESTOR ACTION ALERT: The Schall Law Firm Encourages Investors in ImmunityBio, Inc. with Losses of $500,000 to Contact the Firm

Accesswire July 11, 2023

IBRX ALERT: The Klein Law Firm Announces a Lead Plaintiff Deadline of August 29, 2023 in the Class Action Filed on Behalf of ImmunityBio, Inc. Shareholders

PR Newswire July 11, 2023

The Law Offices of Frank R. Cruz Announces the Filing of a Securities Class Action on Behalf of ImmunityBio, Inc. (IBRX) Investors

Business Wire July 10, 2023

INVESTOR ACTION NOTICE: The Schall Law Firm Encourages Investors in ImmunityBio, Inc. with Losses of $100,000 to Contact the Firm

Newsfile July 10, 2023

Phase 1 Study Indicates Allogeneic Cytokine-Induced Memory-Like Natural Killer Cells Plus N-803 May Induce Tumor Regression in Advanced Head-and-Neck Cancer Patients

Business Wire July 10, 2023